clinical trial · NCT03219268
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
MacroGenics·phase1·completed·n = 277
Advanced Solid TumorsHematologic NeoplasmsOvarian CancerHER2-positive Advanced Solid TumorsNon Small Cell Lung CancerSmall-cell Lung CancerSquamous Cell Carcinoma of Head and NeckCholangiocarcinomatebotelimab 1 mgtebotelimab 3 mgtebotelimab 10 mgtebotelimab 30 mgtebotelimab 120 mgtebotelimab 300 mgtebotelimab 400 mgtebotelimab 600 mg
brief summary
The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed.
started
Aug 18, 2017
primary completion
Feb 8, 2023
completion
Feb 8, 2023
last updated
Dec 21, 2023
official title
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol